Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2009 (2009), Article ID 475390, 5 pages
http://dx.doi.org/10.1155/2009/475390
Case Report

Treatment of Chronic Hepatitis C in a Patient Affected by Systemic Sclerosis

1Department of Oncology, IRCCS Maugeri Foundation, via Maugeri 8, 27100 Pavia, Italy
2Department of Pathology, IRCCS Maugeri Foundation, via Maugeri 8, 27100 Pavia, Italy

Received 7 May 2009; Revised 20 August 2009; Accepted 16 October 2009

Academic Editor: Fabio Marra

Copyright © 2009 Guido Poggi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. B. Strader, T. Wright, D. L. Thomas, and L. B. Seeff, “Diagnosis, management, and treatment of hepatitis C,” Hepatology, vol. 39, no. 4, pp. 1147–1171, 2004. View at Publisher · View at Google Scholar · View at PubMed
  2. M. W. Fried, “Side effects of therapy of hepatitis C and their management,” Hepatology, vol. 36, no. 5, pp. S237–S244, 2002. View at Publisher · View at Google Scholar · View at PubMed
  3. R. Solans, J. A. Bosch, I. Esteban, and M. Villardell, “Systematic sclerosis developing in association with the use of interferon alpha therapy for chronic viral hepatitis,” Clinical and Experimental Rheumatology, vol. 22, no. 5, pp. 625–628, 2004. View at Google Scholar
  4. L. Beretta, M. Caronni, M. Vanoli, and R. Scorza, “Systemic sclerosis after interferon-alfa therapy for myeloproliferative disorders,” British Journal of Dermatology, vol. 147, no. 2, pp. 385–386, 2002. View at Publisher · View at Google Scholar
  5. H. Tahara, A. Kojima, T. Hirokawa et al., “Systemic sclerosis after interferon alphacon-1 therapy for hepatitis C,” Internal Medicine, vol. 46, no. 8, pp. 473–476, 2007. View at Publisher · View at Google Scholar
  6. L. I. Sakkas, B. Xu, C. M. Artlett, S. Lu, S. A. Jimenez, and C. D. Platsoucas, “Oligoclonal T cell expansion in the skin of patients with systemic sclerosis,” Journal of Immunology, vol. 168, no. 7, pp. 3649–3659, 2002. View at Google Scholar
  7. P. J. Johnson and I. G. McFarlane, “Meeting report: international autoimmune hepatitis group,” Hepatology, vol. 18, no. 4, pp. 998–1005, 1993. View at Google Scholar
  8. C. M. Black, A. J. Silman, A. I. Herrick et al., “Interferon-α does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial,” Arthritis & Rheumatism, vol. 42, no. 2, pp. 299–305, 1999. View at Publisher · View at Google Scholar
  9. M. R. Duncan and B. Berman, “Persistence of a reduced-collagen-producing phenotype in cultured scleroderma fibroblasts after short-term exposure to interferons,” Journal of Clinical Investigation, vol. 79, no. 5, pp. 1318–1324, 1987. View at Google Scholar
  10. A. Castilla, J. Prieto, and N. Fausto, “Transforming growth factors β and α in chronic liver disease. Effects of interferon α therapy,” The New England Journal of Medicine, vol. 324, no. 14, pp. 933–940, 1991. View at Google Scholar
  11. R. P. Polisson, G. S. Gilkeson, E. H. Pyun, D. S. Pisetsky, E. A. Smith, and L. S. Simon, “A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels,” Journal of Rheumatology, vol. 23, no. 4, pp. 654–658, 1996. View at Google Scholar
  12. C. Selmi, A. Lleo, M. Zuin, M. Podda, L. Rossaro, and M. E. Gershwin, “Interferon α and its contribution to autoimmunity,” Current Opinion in Investigational Drugs, vol. 7, no. 5, pp. 451–456, 2006. View at Google Scholar
  13. I. Krause, G. Valesini, R. Scrivo, and Y. Shoenfeld, “Autoimmune aspects of cytokine and anticytokine therapies,” American Journal of Medicine, vol. 115, no. 5, pp. 390–397, 2003. View at Publisher · View at Google Scholar
  14. C. Gota and L. Calabrese, “Induction of clinical autoimmune disease by therapeutic interferon-α,” Autoimmunity, vol. 36, no. 8, pp. 511–518, 2003. View at Publisher · View at Google Scholar
  15. D. B. Strader, “Understudied populations with hepatitis C,” Hepatology, vol. 36, no. 5, pp. S226–S236, 2002. View at Publisher · View at Google Scholar · View at PubMed
  16. A. N. Theofilopoulos, R. Baccala, B. Beutler, and D. H. Kono, “Type I interferons (α/β) in immunity and autoimmunity,” Annual Review of Immunology, vol. 23, pp. 307–336, 2005. View at Publisher · View at Google Scholar · View at PubMed
  17. P. Q. Hu, N. Fertig, T. A. Medsger Jr., and T. M. Wright, “Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis,” Arthritis & Rheumatism, vol. 48, no. 5, pp. 1363–1373, 2003. View at Publisher · View at Google Scholar · View at PubMed
  18. M. G. Rumi, F. De Filippi, M. F. Donato, E. Del Ninno, and M. Colombo, “Progressive hepatic fibrosis in healthy carriers of hepatitis C virus with a transaminase breakthrough,” Journal of Viral Hepatitis, vol. 9, no. 1, pp. 71–74, 2001. View at Publisher · View at Google Scholar
  19. M. G. Rumi, F. De Filippi, and C. La Vecchia, “Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients,” Gut, vol. 54, no. 3, pp. 402–406, 2005. View at Publisher · View at Google Scholar · View at PubMed
  20. A. Mangia, R. Santoro, N. Minerva et al., “Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3,” The New England Journal of Medicine, vol. 352, no. 25, pp. 2609–2617, 2005. View at Publisher · View at Google Scholar · View at PubMed
  21. M. J. Nissen, E. Fontanges, Y. Allam, F. Zoulim, C. Trépo, and P. Miossec, “Rheumatological manifestations of hepatitis C: incidence in a rheumatology and non-rheumatology setting and the effect of methotrexate and interferon,” Rheumatology, vol. 44, no. 8, pp. 1016–1020, 2005. View at Publisher · View at Google Scholar · View at PubMed
  22. E. Zuckerman, D. Keren, M. Rozenbaum et al., “Hepatitis C virus-related arthritis: characteristics and response to therapy with interferon alpha,” Clinical and Experimental Rheumatology, vol. 18, no. 5, pp. 579–584, 2000. View at Google Scholar
  23. C. M. Black, A. J. Silman, A. I. Herrick et al., “Interferon-α does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial,” Arthritis & Rheumatism, vol. 42, no. 2, pp. 299–305, 1999. View at Publisher · View at Google Scholar
  24. G. Hassett, P. Harnett, and N. Manolios, “Scleroderma in association with the use of docetaxel (taxotere) for breast cancer,” Clinical and Experimental Rheumatology, vol. 19, no. 2, pp. 197–200, 2001. View at Google Scholar